AzTrials
AzTrials

Opioid Overdose PreventionPROTECT-EDNCT07868393

Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition From the Emergency Department

A study testing PROTECT-ED Care Coordination in people with Opioid Overdose Prevention and HIV Prevention and Care, run by Johns Hopkins University at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition from the Emergency Department (PROTECT-ED) study evaluates an emergency department-based implementation strategy designed to improve delivery of evidence-based overdose and HIV prevention services during community re-entry. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
PROTECT-ED Care Coordination
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteUnited States
Study dates
1 Nov 2026to 1 Oct 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Are 18 years of age or older.
  • Present to the Johns Hopkins Hospital Emergency Department.
  • Have been released within the previous 180 days from a prison, jail, juvenile detention facility, immigration detention facility, halfway house, residential reentry center, or other correctional setting. Recent incarceration may be confirmed through participant self-report, electronic medical record documentation, the Victim Information and Notification Everyday (VINE) system, or other available documentation. Participant self-report alone is sufficient to establish eligibility.
  • Meet criteria for opioid use disorder or hazardous opioid use and are considered appropriate for evaluation for medications for opioid use disorder (MOUD) or are at risk for HIV acquisition.
  • Able to speak and understand communicate in English sufficiently to provide informed consent and complete study assessments.
  • Provide informed consent.
  • Have a reliable telephone number for study follow-up.

Who cannot join

  • Inability to provide informed consent during the index emergency department encounter.
  • Lack of a reliable telephone number for study follow-up.
  • Prior enrollment in the PROTECT-ED study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Bhakti Hansoti, MBChB, PhD, MPH contact

410-955-5000

bhansot1@jh.edu

Chris Hoffmann, MD, MSc, MPH contact

choffmann@jhmi.edu

United States1 site
  • The Johns Hopkins Hospital Emergency Department

    Baltimore, Maryland, 21287

Other trials in United States

About this study

Official title: Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition From the Emergency Department (PROTECT-ED)

The Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition from the Emergency Department (PROTECT-ED) study evaluates an emergency department-based implementation strategy designed to improve delivery of evidence-based overdose and HIV prevention services during community re-entry.

Read the detailed description
  1. Background Individuals returning to the community following incarceration experience one of the highest periods of preventable morbidity and mortality observed in clinical medicine. During the weeks and months following release from correctional facilities, rates of fatal opioid overdose increase by as much as 10- to 100-fold, while the risk of HIV acquisition is estimated to be 6- to 20-fold higher than that of the general population. These risks reflect the convergence of opioid use disorder, disrupted healthcare access, unstable housing, poverty, stigma, untreated mental illness, and fragmented transitions between correctional and community healthcare systems. Although effective biomedical interventions exist--including medications for opioid use disorder (MOUD) and HIV pre-exposure prophylaxis (PrEP)--many recently incarcerated individuals do not successfully engage in or remain connected to these services during community re-entry. Historically, efforts to improve continuity of care have focused on correctional health systems and community re-entry programs. These approaches have demonstrated important benefits but remain limited by incomplete implementation, inconsistent access across jurisdictions, and substantial loss to follow-up during the transition from incarceration to community living. Consequently, many individuals with ongoing opioid-related and HIV-related risks remain disconnected from preventive healthcare during the period of greatest vulnerability. The emergency department represents an underutilized opportunity to address this implementation gap. Between one-quarter and one-half of individuals released from incarceration seek care in an emergency department within the first year following release, and for many, the emergency department serves as the only point of contact with the healthcare system. Contemporary emergency departments have increasingly expanded beyond episodic acute care to incorporate evidence-based public health interventions, including overdose prevention, medications for opioid use disorder, HIV screening, and initiation of HIV pre-exposure prophylaxis. These developments position the emergency department as a critical venue for delivering integrated preventive services to individuals who may otherwise remain unreached by traditional healthcare systems. PROTECT-ED was developed to leverage this unique healthcare touchpoint by integrating peer-delivered prevention services, evidence-based biomedical prevention, harm reduction, and facilitated linkage to ongoing community care into a single emergency department encounter. Rather than evaluating the efficacy of MOUD or PrEP--which are already supported by extensive evidence--the study evaluates an implementation strategy designed to improve the reach, uptake, and continuity of these established interventions among recently incarcerated individuals. The intervention is informed by the Behavioral Model for Vulnerable Populations, which recognizes that healthcare utilization is shaped by predisposing characteristics, enabling resources, and perceived and evaluated need for care. By addressing barriers across each of these domains during an existing emergency department visit, PROTECT-ED seeks to improve engagement with preventive services during community re-entry.
  2. Study Objectives As a clinical trial planning study, the purpose of PROTECT-ED is to refine the intervention through participatory prototyping, evaluate the feasibility and preliminary clinical outcomes of implementation, and characterize implementation processes that will inform a future multicenter effectiveness-implementation trial. The knowledge generated through this study will provide the empirical and operational foundation necessary to scale emergency department-based overdose and HIV prevention strategies for individuals returning from incarceration nationally. The overarching objective of PROTECT-ED is to refine and evaluate an emergency department-based implementation strategy designed to improve uptake of evidence-based overdose and HIV prevention services among adults recently released from incarceration. Specifically, this study seeks to refine the intervention through stakeholder engagement, evaluate the feasibility and preliminary clinical outcomes of implementation, and characterize implementation processes to inform a future multi-center effectiveness-implementation trial.
  3. Aims The study consists of three integrated aims. Aim 1 focuses on refinement of the PROTECT-ED intervention through participatory prototyping involving individuals with lived experience, clinicians, correctional health partners, community-based organizations, and other stakeholders. Aim 2 evaluates the feasibility and preliminary clinical outcomes of the refined PROTECT-ED intervention through a prospective implementation trial enrolling 120 adults recently released from incarceration. Aim 3 evaluates implementation outcomes using mixed methods guided by the Practical, Robust, Implementation and Sustainability Model (PRISM). Quantitative and qualitative findings will characterize intervention reach, acceptability, contextual determinants, and implementation barriers and facilitators.
  4. Study Setting The study will be conducted within the Johns Hopkins Hospital Emergency Department, an urban, academic emergency department that evaluates approximately 60,000 adult patients annually. The emergency department has established clinical pathways for the identification and management of opioid use disorder, universal opt-out HIV screening, initiation of HIV pre-exposure prophylaxis, peer recovery services, and linkage to addiction medicine and infectious diseases care. The Johns Hopkins Hospital Emergency Department serves a large population of individuals affected by opioid use disorder, homelessness, structural vulnerability, and criminal-legal involvement.
  5. Conceptual Framework The PROTECT-ED intervention is informed by the Behavioral Model for Vulnerable Populations, which recognizes that healthcare utilization is influenced by predisposing characteristics, enabling resources, and perceived and evaluated need for care. The intervention seeks to improve engagement with overdose and HIV prevention services by addressing barriers across each of these domains during an emergency department encounter. Evaluation of implementation outcomes is guided by the Practical, Robust, Implementation and Sustainability Model (PRISM). PRISM provides a framework for understanding the interaction between the intervention, recipients, organizational context, external environment, and implementation infrastructure, and will inform refinement of the intervention and planning for future scale-up.
  6. Study Timeline The anticipated duration of the study is 36 months. Year 1: Regulatory approvals, participatory prototyping (Aim 1), intervention refinement, and study start-up.

Years 2-3: Participant enrollment, intervention delivery, follow-up assessments, and implementation evaluation (Aims 2 and 3).

Year 3: Data analysis, dissemination of findings, and development of a future multicenter effectiveness-implementation trial.

Being tested
PROTECT-ED Care Coordination
Keywords
Harm reduction, OUD, Justice-Involved Individuals, Healthcare Engagement
Medical subject headings
Harm Reduction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PROTECT-ED Care CoordinationBehavioural

    Participants will receive the PROTECT-ED intervention during the index emergency department encounter. The intervention consists of systematic identification; peer-delivered prevention services; same-day offer and initiation of MOUD and PrEP, when clinically appropriate; harm reduction services; and facilitated linkage to ongoing community care. Clinical decisions regarding medication initiation remain the responsibility of the treating emergency department clinician. The ED clinician would prescribe medication as part of ED care delivery, this would include reviewing eligibility and dosing with the ED pharmacist.

Study groups in NCT07868393
Study groupRoleWhat they receive
Aim 2 Study ParticipantsOtherParticipants will receive the PROTECT-ED intervention during the index emergency department encounter. The intervention consists of systematic identification; peer-delivered prevention services; same-day offer and initiation of MOUD and PrEP, when clinically appropriate; harm reduction services; and facilitated linkage to ongoing community care. Clinical decisions regarding medication initiation remain the responsibility of the treating emergency department clinician. The ED clinician would prescribe medication as part of ED care delivery, this would include reviewing eligibility and dosing with the ED pharmacist.
Receives: Behavioral: PROTECT-ED Care Coordination

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MOUD uptake

    Proportion of participants initiating MOUD

    Measured: 0-26 Weeks

  2. MOUD and PrEP Uptake

    Proportion of participants initiating MOUD and PrEP

    Measured: 0-26 Weeks

  3. PrEP Uptake

    Proportion of participants initiating PrEP

    Measured: 0-26 Weeks

Secondary outcomes (5)
  1. MOUD persistence at 6 months

    Proportion of participants on MOUD at 6 months among those who initiated

    Measured: 26 Weeks

  2. PrEP persistence at 6 months

    Proportion of participants on PrEP at 6 months among those who initiated

    Measured: 26 Weeks

  3. Participants with Repeat emergency department utilization

    Repeat emergency department utilization across Baltimore City

    Measured: 0-26 Weeks

  4. Opioid overdose events

    Proportion of participants with 1+ opioid overdose events

    Measured: 0-26 Weeks

  5. Linkage and engagement in longitudinal care

    Proportion of participants linked to care

    Measured: 0-26 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion1 Oct 2027 (estimated)
  4. Study completion1 Oct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07868393
Sponsor's protocol ID
IRB00574066
Other IDs
1R34DA067263-01
Acronym
PROTECT-ED
Status last verified
Oct 2026
First submitted
5 Oct 2026
Last updated
9 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Vargas C, Zorbas C, Longworth GR, Ugalde A, Needham C, Sunil A, Venegas Hargous C, Bennett R, Forrester-Bowling T, Cardoso Richter AP, Allender S. Exploring co-design: a systematic review of concepts, processes, models, and frameworks used in public health research. J Public Health (Oxf). 2025 Dec 1;47(4):e616-e639. doi: 10.1093/pubmed/fdaf084.

    PubMed 40796276
  • Rousham E, Pareja RG, Creed-Kanashiro HM, Bartolini R, Pradeilles R, Ortega-Roman D, Holdsworth M, Griffiths P, Verdezoto N. Designing intervention prototypes to improve infant and young child nutrition in Peru: a participatory design study protocol. BMJ Open. 2023 Dec 9;13(12):e071280. doi: 10.1136/bmjopen-2022-071280.

    PubMed 38070935
  • Goldfarb DA. Surgical adrenal disorders. Semin Nephrol. 1994 Nov;14(6):570-9. No abstract available.

    PubMed 7855463
  • Gelberg L, Andersen RM, Leake BD. The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000 Feb;34(6):1273-302.

    PubMed 10654830
  • Eswaran V, Raven MC, Wang RC, Cawley C, Izenberg JM, Kanzaria HK. Understanding the association between frequent emergency department use and jail incarceration: A cross-sectional analysis. Acad Emerg Med. 2022 May;29(5):606-614. doi: 10.1111/acem.14437. Epub 2022 Feb 10.

    PubMed 35064709
  • Easter MM, Schramm-Sapyta NL, Tackett MA, Larsen IG, Tang B, Ralph MA, Huynh LN. Reliance on Community Emergency Departments by People Ever Detained in Jail: Retrospective Cross-Sectional Study. J Correct Health Care. 2023 Aug;29(4):282-292. doi: 10.1089/jchc.22.02.0011. Epub 2023 Jun 19.

    PubMed 37335965
  • Bazin H. Is antiinfectious defence thymus-dependent? Ann Inst Pasteur Immunol. 1988 Mar-Apr;139(2):187-9. doi: 10.1016/0769-2625(88)90040-2. No abstract available.

    PubMed 3259426
  • Humphreys J, Ahalt C, Stijacic-Cenzer I, Widera E, Williams B. Six-Month Emergency Department Use among Older Adults Following Jail Incarceration. J Urban Health. 2018 Aug;95(4):523-533. doi: 10.1007/s11524-017-0208-4.

    PubMed 29204845
  • Meyer JP, Qiu J, Chen NE, Larkin GL, Altice FL. Frequent emergency department use among released prisoners with human immunodeficiency virus: characterization including a novel multimorbidity index. Acad Emerg Med. 2013 Jan;20(1):79-88. doi: 10.1111/acem.12054.

    PubMed 23570481
  • Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013 Feb;26(1):10-6. doi: 10.1097/QCO.0b013e32835c1dd0.

    PubMed 23221766
  • Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. Am J Public Health. 2015 Jul;105(7):e5-16. doi: 10.2105/AJPH.2015.302635. Epub 2015 May 14.

    PubMed 25973818
  • Spittal MJ, Forsyth S, Pirkis J, Alati R, Kinner SA. Suicide in adults released from prison in Queensland, Australia: a cohort study. J Epidemiol Community Health. 2014 Oct;68(10):993-8. doi: 10.1136/jech-2014-204295. Epub 2014 Jul 9.

    PubMed 25009152
  • Wang EA, Wang Y, Krumholz HM. A high risk of hospitalization following release from correctional facilities in Medicare beneficiaries: a retrospective matched cohort study, 2002 to 2010. JAMA Intern Med. 2013 Sep 23;173(17):1621-8. doi: 10.1001/jamainternmed.2013.9008.

    PubMed 23877707
  • Hartung DM, McCracken CM, Nguyen T, Kempany K, Waddell EN. Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data. J Subst Use Addict Treat. 2023 Apr;147:208971. doi: 10.1016/j.josat.2023.208971. Epub 2023 Feb 10.

    PubMed 36821990

Questions about this trial

What is this clinical trial studying?

A study testing PROTECT-ED Care Coordination in people with Opioid Overdose Prevention and HIV Prevention and Care, run by Johns Hopkins University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Bhakti Hansoti, MBChB, PhD, MPH (410-955-5000, bhansot1@jh.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MOUD uptake (time frame: 0-26 Weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07868393, which also lists 14 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in